TELETRADER News
6/23, 7:24 AM (Source: TeleTrader)
more TeleTrader news

Sanofi expects COVID-19 vaccine approval in H1 2021

Sanofi expects that its recombinant protein-based COVID-19 vaccine developed in collaboration with GlaxoSmithKline will be approved by regulators in the first six months of next year, the company announced on Tuesday. The French pharmaceutical giant added that it has the capacity to produce 1 billion doses of the vaccine annually. Initial phase 1/2 trials for the recombinant protein-based vaccine are likely to begin in September, Sanofi added.

Furthermore, the firm noted its other coronavirus vaccine candidate, based on messenger RNA (mRNA) technology from Translate Bio will most likely be available for initial testing in the last quarter of 2020. Sanofi doesn't see the mRNA vaccine being approved before the second half of 2021. Additionally, the company pointed out that, even though the mRNA is considered to be by industry experts "among the most promising" COVID-19 vaccines, it will only be able to produce between 90 million and 360 million doses of the vaccine per year.

Breaking the News / VP